|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
U-M's Daniel Hayes wins inaugural Gianni Bonadonna Breast Cancer Award- added 8/16/07
ALEXANDRIA, Va. - The American Society of Clinical Oncology and the ASCO Foundation today announced the winner of the inaugural Gianni Bonadonna Breast Cancer Award. Daniel F. Hayes, M.D., clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center, will accept the award and present the first Bonadonna Award lecture at the upcoming 2007 Breast Cancer Symposium, being held Sept. 7-8 in San Francisco.
"I am honored to be the first recipient of the Gianni Bonadonna Breast Cancer Award," says Hayes, professor of internal medicine at U-M Medical School. "Few researchers have had the impact on cancer advancements that Dr. Bonadonna has, and I accept this award with the full intent of honoring his legacy and life's work with continued efforts to improve the care and treatment of patients."
During the past two decades, Hayes has been focused on bridging the gap between laboratory and clinical research. He has been influential in both clinical and laboratory studies of the diagnosis and treatment of breast cancer. He has become an internationally recognized leader in the use of the CA15-3 blood test, which is currently used worldwide to evaluate patients with breast cancer, as well as leading efforts with other tumor markers, such as HER-2. More recently, he and his colleagues reported groundbreaking results in two areas of research: circulating tumor cells in metastatic breast cancer and the pharmacogenomics of tamoxifen.
Hayes is widely considered to be an expert in the field of clinical breast cancer research, especially in regard to new hormonal and chemotherapeutic treatments, and, in particular, development, evaluation and clinical use of tumor markers. He was a charter member of ASCO's Tumor Marker Guideline Expert Panel, which he has co-chaired for the past three years. He also lectures and publishes extensively regarding the management of patients with breast cancer.
Unveiled at ASCO's 43rd annual meeting this past June in Chicago and supported by a grant from GlaxoSmithKline Oncology, the Gianni Bonadonna Breast Cancer Award and Fellowship is a $10,000 annual award that recognizes an active clinical or translational researcher with a distinguished record of accomplishments in advancing the field of breast cancer. The Bonadonna Award is comprised of an endowment, allowing the award to be available for many years to come, and it is accompanied by a one-year, $50,000 Fellowship Grant that will be awarded by The ASCO Foundation to an early-career breast cancer researcher who will work in the lab at the recipient's institution. The fellow will be announced at a later date.
"Grants and awards like these are a vital component to continued progress in cancer research," says Allen S. Lichter, M.D., executive vice president and CEO of ASCO. "Dr. Hayes' work has led to some of the most important advances in recent years in cancer treatment, and we know that his forthcoming efforts will lead to more. People living with cancer - and the 1.45 million more who will be diagnosed this year - can take some comfort in knowing that Dan Hayes, and researchers like him all around the globe, are working every day for new treatments and new cancer regimens."
The award is named after renowned international researcher Gianni Bonadonna, M.D., whose work has led to the development of successful and widely used treatment regimens. Bonadonna conducted the pivotal cyclophosphamide, methotrexate and fluorouracil (CMF) trial which ushered in the widespread acceptance of adjuvant chemotherapy as part of the curative treatment of breast cancer; a finding which changed the course of how breast cancer is treated. Additionally, Bonadonna designed and conducted the first clinical trials exploring the use of doxorubicin and developed the doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) protocol, which remains the gold standard for treating Hodgkin's disease. Bonadonna works at the Instituto Nazionale Tumori in Milan, Italy.
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. ASCO's nearly 25,000 members from the United States and abroad set the standard for patient care and lead the efforts to discover more effective cancer treatments, increase funding for clinical and translational research and, ultimately, improve cancer care for the estimated 10 million people diagnosed with cancer worldwide each year. ASCO publishes the Journal of Clinical Oncology, the preeminent, peer-reviewed medical journal on clinical cancer research and produces People Living With Cancer, a comprehensive consumer Web site providing oncologist-vetted cancer information to help patients and families make informed health care decisions.
The ASCO Foundation is a 501(c)(3) charitable organization that supports educational programs of the highest quality in cancer care and prevention; facilitates the dissemination of information about cancer and cancer treatment to patients and their families; and, through its grants program, supports, encourages, and recognizes excellence in clinical research in the field of oncology.
CONTACT: Ken Goldman: 703-797-1930